Shareholders Approve Doubling of Authorized Shares to 200 Million

summarizeSummary

Shareholders approved a major increase in authorized common stock, providing Protara Therapeutics with significant capacity for future capital raises but also creating substantial potential for dilution.

check_boxKey Events

• Authorized Shares Doubled

  Shareholders approved an amendment to the company's certificate of incorporation, increasing the authorized common stock from 100,000,000 to 200,000,000 shares. This follows the PRE 14A filing on 2026-04-17 which sought this approval.

• Significant Potential Dilution

  The newly authorized 100,000,000 shares represent a potential dilution of approximately 181% relative to the 55,060,500 shares outstanding as of April 15, 2026.

• Equity Incentive Plan Approved

  An amendment to the 2024 Equity Incentive Plan was approved, increasing the pool of shares available for equity awards to employees and directors.

• Officer Exculpation Approved

  Shareholders approved an amendment to the certificate of incorporation allowing officer exculpation, as permitted by Delaware law.

auto_awesomeAnalysis

Protara Therapeutics' shareholders approved a significant increase in authorized common stock, doubling it from 100 million to 200 million shares. This authorization provides the company with substantial flexibility to issue new shares for future capital raises, potentially enabling further funding for its clinical programs and operations. While it grants crucial financial runway, it also introduces a considerable potential for dilution for existing shareholders, as the newly authorized shares represent a large percentage of current outstanding shares.